NEW YORK and LONDON, January 5, 2016 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, announced an update …
Akari Therapeutics Announces Update from Non-Human Primate Safety Study at International PNH Interest Group 10th Annual Scientific Meeting
NEW YORK and LONDON, December 7, 2015 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, provided an update …
Akari Therapeutics Announces Upcoming Data Presentations at the 57th American Society of Hematology Annual Meeting
NEW YORK and LONDON, November 5, 2015 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, announced today …
Akari Therapeutics Closes $75 Million Private Placement
NEW YORK and LONDON, September 21, 2015 AAkari Therapeutics (formerly known as Celsus Therapeutics plc) (NASDAQ: AKTX), an emerging growth, …
[Read more...] about Akari Therapeutics Closes $75 Million Private Placement
Celsus Therapeutics and Volution Immuno Pharmaceuticals Announce Completion of Acquisition and Formation of Complement C5 Inhibitor Company Akari Therapeutics Plc
NEW YORK and LONDON, September 18, 2015 Celsus Therapeutics Plc (NASDAQ: CLTX) and Volution Immuno Pharmaceuticals SA today announced that, following …
